| |
|
| |
Longevity Biotech Pitch Night - New York
Hosted by the Longevity Investor Network & Lifespan Research Institute
When: Thursday, November 19, 2026
Where: [RSVP to see venue], New York City
About the Event:
Join us for an exclusive evening in New York as we showcase some of the most promising longevity startups shaping the future.
A handpicked group of companies will take the stage to share their vision, scientific breakthroughs, & growth potential in front of a curated audience of leading investors. This is a unique opportunity to get a first look at innovative ventures before they make their mark.
What to Expect
Startup Pitches - Hear directly from founders building the next big thing in longevity.
Investor-Only Access - An intimate, invite-only setting designed for meaningful connections.
Agenda:
5:00PM - 6:20PM: Registration / Networking
6:20PM - 6:30PM: Opening Remarks - Keith Comito (LRI/LIN)
6:30PM - 6:50PM: Repair Biotechnologies Presentation
6:50PM - 7:10PM: Unmask Therapeutics Presentation
7:10PM - 7:30PM: Havia Bio Presentation
7:30PM - 7:55PM: Break / Networking
7:55PM - 8:00PM: A few words from our CEO (LRI/LIN)
8:00PM - 8:20PM: Klona Biotech Presentation
8:20PM - 8:40PM: Pitch Presentation #5 (Company 6 Pitch)
8:40PM - 9:15PM: Break / Networking / Clean-up
Who's Pitching
Repair Biotechnologies: Repair Biotechnologies develops the proprietary Cholesterol Degrading Platform (CDP) that clears toxic excess free cholesterol inside cells, an undruggable target that existing therapies cannot meaningfully address. Cardiovascular disease accounts for ~27% of global mortality. Current treatments slow plaque growth but cannot reverse it. Repair's lead drugs have demonstrated 20-30% plaque regression & 100% gain in treadmill endurance in just 6 weeks in preclinical models of severe atherosclerosis, improvements that continue to grow after treatment cessation. The company has completed a successful non-human primate study showing safety & favorable metabolic changes, has received FDA Orphan Drug Designation, & held a positive pre-IND meeting with the FDA. The pipeline extends to MASH (liver disease), neurodegeneration, & ocular conditions. The company was recently awarded Rare Disease Evidence Principles (RDEP) program eligibility by the FDA, allowing for drug approval after a single clinical trial.
Unmask Therapeutics: Unmask Therapeutics is a spinout of the Lifespan Research Institute developing a novel small-molecule therapeutic for genetic mitochondrial diseases, with the potential to address an underlying cause of disease rather than just manage symptoms. Its initial target market is patients with rare, severe mitochondrial disorders, an area of significant unmet medical need, with potential longer-term applications in broader mitochondrial dysfunction & age-related disease. They currently have strong in-vitro efficacy data & in-vivo pharmacokinetics, & working on pivotal preclinical in-vivo efficacy study in disease-model mice.
Havia Bio is building the missing delivery layer for regenerative medicine. Many promising biologics, from peptides & growth factors to exosomes & stem cells, clear from the body before they can work. Havia's HYALUTE platform uses engineered hyaluronic acid microparticles to keep therapies at the target site & release them steadily over one to six months. Its lead product, VIA101 is a once-a-month, non-hormonal vaginal film for genitourinary syndrome of menopause. GSM affects an estimated 17 million postmenopausal women, & most of those who seek treatment are dissatisfied with current options. Havia has clean safety data in two large-animal species & five patent applications. It is working toward FDA De Novo clearance for VIA101 while advancing platform applications in sports medicine, ophthalmology, aesthetics, & cardiovascular disease.
Klona Biotech is building the technology needed to 3D print the human limb. Most surgical replacement & reconstruction involves orthopedic tissue like bone, cartilage, tendons, & ligaments, yet today's bioprinters were built for soft, delicate structures like the liver & can't produce tissue strong enough for load-bearing repair. Klona's patent-pending Klotho platform combines in-house developed hardware, patent-pending printing materials, & custom AI software to 3D print implants that are both regenerative & mechanically robust. Mechanically, Klona's printed materials outperform those produced with conventional bioprinters by up to 1000 times, even outperforming the properties of actual tendon. The company's first product, the FIBRAMEND implant, targets the more than 500,000 rotator cuff repair procedures performed each year, with a target FDA clearance date of 2028 through the 510(k) pathway. Beyond FIBRAMEND, Klona's platform uses an AI-in-the-loop system to accelerate the design & production of orthopedic implants, with plans to target the meniscus, living tissue-engineered implants, & eventually the capability to print every tissue making up the human arm.
Company 5 Pitch: [Coming Soon / Description to come]
Investor Attendees:
Investors From: Longevity Investor Network, Age1, ContinuumHealthVC, DraperVC, LunarVentures, NFX, PioneerFundVC, PearVC, InsightPartners, XPrize, OutsidersFund, HCVC, BackedVC, LongevityTechFund, Longevity Vision Fund, BoxOne Ventures, SOS Ventures, Maximon, Juvenescence, 5AM Ventures, CambrianBio, AltosLabs, Canaan Partners, LongeVC, Methuselah Foundation, CurieBio, Centenarian Fund, Formic Ventures, Khosla Ventures, Prime Movers Lab, Life Science Angels, Emerging Longevity Ventures, HOF Capital, OrbiMed, IndieBio, Apollo Health Ventures, & more!
Register Your Interest on our Luma page! If you've received an invitation, please RSVP to confirm your spot. Space is limited.
Lifespan Research Institute ("LRI") is a 501(c)(3) nonprofit organization focused on the defeat of age-related disease & the extension of healthy human lifespan - through raising funds & awareness for scientific work addressing the root causes of the aging process, building a thriving ecosystem of mission aligned stakeholders which can be mobilized to strategic action, & spearheading relevant research projects directly. We work to identify, develop, & promote initiatives with outsized impact & the greatest potential to realize widespread access to regenerative medicine solutions targeting the disabilities & diseases of aging.
More info: https://lifespan.io/
The Longevity Investor Network is an initiative of Lifespan Research Institute, a 501(c)(3) nonprofit formed through the merger of SENS Research Foundation & Lifespan.io.
More info: https://lifespan.io/longevity-investor-network/
|
|
|
|
|
|
|
|
